Pharma / Med Tech / Health innovation updates
Joined July 2009
- Tweets1.6K
- Following308
- Followers34.7K
- Likes322
BMS' LPA1 antagonist admilparant met its primary endpoint in an IPF study at the 60mg dose, showing a statistically significant improvement in forced vital capacity over placebo, though a miss at the higher dose leaves analysts awaiting full data. IPF has been one of the most treatment-resistant conditions in respiratory medicine. A new mechanism class getting a Phase 3 win is significant news for respiratory pharmacists and patients who have exhausted current options.
#IdiopathicPulmonaryFibrosis #RespiratoryPharmacy #ClinicalTrials #BMS #PharmacyTwitter
biospace.com/drug-developmen…
1
474
New Bloomberg Intelligence data shows GLP-1 pill users curbed snacking less than injection users: 74% versus 80% for salty snacks, and 76% versus 82% for baked goods. Route of administration is now a clinical decision, not just a patient preference.
#GLP1 #OralGLP1 #ObesityMedicine #PharmacyTwitter
bloomberg.com/news/articles/…
Yale researchers have identified an unexpected mechanism that challenges a long-held assumption about the brain’s hunger circuitry, and it may fundamentally change how we understand GLP-1s. We have been prescribing these drugs for years. We still do not fully know how they work in the brain. The pharmacology of this class keeps rewriting itself.
#GLP1 #Neuropharmacology #ObesityMedicine #PharmacyTwitter
news.yale.edu/2026/08/10/new…
1
1
614
Pharmacy Updates retweeted
The GLP-1 family of drugs is emerging to be potentially transformative for addiction medicine. This new @jclinicalinvest paper succinctly reviews the biology, epidemiology, randomized trials, and the gaps needed to fill in @Lorenzo__Leggio
jci.org/articles/view/211153
Pharmacy Updates retweeted
Brazilian seizures of illegal GLP-1 weight-loss drugs are soaring, and health officials worry the country may be one of the most exposed to the drugs' unintended consequences, as customers are driven toward the cheaper, smuggled and unapproved injections reut.rs/4cih8vX
Pharmacy Updates retweeted
A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. Full study results: nej.md/4wW5wGB
ALT A graph showing the circulating C-peptide concentrations before and after transplantation and corresponding glucose management indicator (GMI) values (with each GMI calculated on the basis of the average glucose level over a period of 14 days).
Pharmacy Updates retweeted
While GLP-1 medicines can be incredibly effective, it's natural to have questions raised about the overall safety. Currently, the main side effects shown are primarily found with abdominal pain, vision changes, or quick mood changes. Also, these medications need to be continued long-term, and stopping often leads to weight and risk-factor regain.
To learn more in-depth about the risk factors involved, tap the link: mdsc.pe/4xXwChq
Merck and Moderna’s personalised mRNA cancer vaccine Intismeran, combined with Keytruda, slowed melanoma recurrence and its spread to other organs in a Phase 3 trial of over 1,000 patients. This is the first randomised Phase 3 trial to definitively prove the benefit of neoantigen vaccines.
#mRNA #OncologyPharmacy #CancerVaccine #Melanoma #PharmacyTwitter
statnews.com/2026/08/19/mrna…
4
690
Results from a late-stage study on generalised anxiety disorder were described as a “clean win” by analysts, who believe Definium has a drug with multibillion-dollar sales potential. GAD is one of the most undertreated conditions in community pharmacy.
#AnxietyDisorder #ClinicalTrials #Psychiatry #ClinicalPharmacy #PharmacyTwitter
biopharmadive.com/news/defin…
1
534
Marijuana’s rescheduling to Schedule III is now reshaping clinical practice, research pathways and insurance coverage in ways pharmacists have not had to navigate before. A drug that was Schedule I last year is now on a formulary trajectory.
#Cannabis #Schedule3 #ClinicalPharmacy #PharmacyTwitter
pharmacytimes.com/view/marij…
673
The FDA just approved Moderna’s mFLUSIVA (mRNA-1010), the first ever mRNA-based influenza vaccine, for adults aged 50 and over, showing approximately 26–27% relative efficacy versus a standard-dose vaccine. The mRNA era didn’t stop with COVID.
#mRNA #InfluenzaVaccine #Moderna #PharmacyTwitter #ClinicalPharmacy
pharmexec.com/view/questions…
675
Pharmacy Updates retweeted
Engineered CAR-T cells induce long-lasting remission in rheumatoid arthritis with a single infusion
worldpharmanews.com/research…
The FDA just approved Moderna’s mFLUSIVA (mRNA-1010), the first ever mRNA-based influenza vaccine, for adults aged 50 and over, showing approximately 26–27% relative efficacy versus a standard-dose vaccine. The mRNA era didn’t stop with COVID.
#mRNA #InfluenzaVaccine #Moderna #PharmacyTwitter #ClinicalPharmacy
pharmexec.com/view/questions…
2
680
Eli Lilly bets $3.8B on psychedelics 🧠
Lilly just dropped $3.8 billion on a psychedelics deal — the same week an oral PCSK9 inhibitor got approved. The largest pharma company on earth is now in the psychedelic medicine space.
#PsychedelicMedicine #EliLilly #ClinicalPharmacy #PharmacyTwitter
lifesciencedaily.news/weekly…
500
Brand new lung cancer drug approved.
The FDA approved zidesamtinib for previously treated ROS1-positive non-small cell lung cancer — a targeted therapy showing durable responses and strong activity against brain metastases. Brain mets in NSCLC have historically been a therapeutic dead end. Not anymore. Oncology pharmacists.
#LungCancer #TargetedTherapy #OncologyPharmacy #FDA #PharmacyTwitter
afs.lambda-bio.com/blog/top-…
494
Pharmacy Updates retweeted
Menopausal hormone treatment and breast cancer thelancet.com/journals/landi…
#MHT #HRT #breastcancer #Womenshealth
🚨 Medicare just changed the game for GLP-1s. As of July 1, eligible Medicare Part D beneficiaries can now access Wegovy, Zepbound and Foundayo for weight loss — for a $50 monthly copay through the new GLP-1 Bridge program.
This is the first time Medicare has ever covered GLP-1s prescribed solely for obesity.
The program runs through December 31, 2027 — after which patients could lose access unless CMS extends it or Congress changes the law.
Pharmacists — your Medicare patients are about to start asking questions. Know the eligibility criteria, the prior authorisation requirements, and that the $50 copay does NOT count toward their Part D out-of-pocket limit. Counsel accordingly. 👇
#GLP1 #Medicare #ObesityMedicine #PharmacyTwitter #ClinicalPharmacy
cms.gov/medicare/coverage/pr…
Pharmacy Updates retweeted
Among patients with multivessel coronary artery disease who were in stable condition 1 year after stenting, an additional year of DAPT led to a lower risk of ischemic events than aspirin alone, without increased bleeding. Full DAPT-MVD trial results: nej.md/4wLDIox
Editorial: Balancing the Scales — Extended DAPT in Coronary Artery Disease nej.md/4gAVqpZ
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease." The graph shows major adverse cardiovascular and cerebrovascular events. The trial name, DAPT-MVD, is in parentheses after the title. The NEJM identity sits at the bottom.
Pharmacy Updates retweeted
"The world’s largest drugmaker is betting big on preventive medicines"
The future of medicine is not just to come up with more treatments, which has been the fixation for pharma companies. It can and should be to prevent diseases, with what I call "prevmeds." We're starting to see a shift.
economist.com/business/2026/…
🧬 One infusion. One time. For life.
Eli Lilly’s VERVE-102 — a PCSK9 base-editing gene therapy — cut LDL cholesterol by up to 62% and PCSK9 protein by up to 88% from a single IV infusion, with effects sustained for up to 18 months. Published in NEJM. Presented at EAS 2026.
Approximately half of all patients prescribed lipid-lowering therapy discontinue within a year. VERVE-102 doesn’t ask patients to remember a pill. It edits the problem out of their DNA.
No treatment-related serious adverse events. No clinically significant lab abnormalities. Phase 2 is coming.
The statin era may have a sunset date. Are pharmacists ready for a world where cholesterol management is a one-time conversation? 👇
#GeneEditing #VERVE102 #Cardiology #LDL #PCSK9 #PharmacyTwitter #NEJM
investor.lilly.com/news-rele…
